Filtered By:
Procedure: Dialysis
This page shows you your search results in order of relevance. This is page number 15.
Order by Relevance | Date
Total 32996 results found since Jan 2013.
Interventions for renal vasculitis in adults.
CONCLUSIONS: Plasma exchange was effective in patients with severe AKI secondary to vasculitis. Pulse cyclophosphamide may result in an increased risk of relapse when compared to continuous oral use but a reduced total dose. Whilst CPA is standard induction treatment, rituximab and MMF were also effective. AZA, methotrexate and leflunomide were effective as maintenance therapy. Further studies are required to more clearly delineate the appropriate place of newer agents within an evidence-based therapeutic strategy.
PMID: 31927782 [PubMed - in process]
Source: Cochrane Database of Systematic Reviews - January 12, 2020 Category: General Medicine Authors: Walters GD, Willis NS, Cooper TE, Craig JC Tags: Cochrane Database Syst Rev Source Type: research
Oral protein-based supplements versus placebo or no treatment for people with chronic kidney disease requiring dialysis.
CONCLUSIONS: Overall, it is likely that oral protein-based nutritional supplements increase both mean change in serum albumin and serum albumin at end of intervention and may improve serum prealbumin and mid-arm muscle circumference. The improvement in serum albumin was more evident in haemodialysis and malnourished participants. However, it remains uncertain whether these results translate to improvement in nutritional status and clinically relevant outcomes such as death. Large well-designed RCTs in this population are required.
PMID: 32390133 [PubMed - in process]
Source: Cochrane Database of Systematic Reviews - May 10, 2020 Category: General Medicine Authors: Mah JY, Choy SW, Roberts MA, Desai AM, Corken M, Gwini SM, McMahon LP Tags: Cochrane Database Syst Rev Source Type: research
Potassium binders for chronic hyperkalaemia in people with chronic kidney disease.
CONCLUSIONS: Evidence supporting clinical decision-making for different potassium binders to treat chronic hyperkalaemia in adults with CKD is of low certainty; no studies were identified in children. Available studies have not been designed to measure treatment effects on clinical outcomes such as cardiac arrhythmias or major GI symptoms. This review suggests the need for a large, adequately powered study of potassium binders versus placebo that assesses clinical outcomes of relevance to patients, clinicians and policy-makers. This data could be used to assess cost-effectiveness, given the lack of definitive studies and t...
Source: Cochrane Database of Systematic Reviews - June 25, 2020 Category: General Medicine Authors: Natale P, Palmer SC, Ruospo M, Saglimbene VM, Strippoli GF Tags: Cochrane Database Syst Rev Source Type: research
Etiology and Management of Acute Metabolic Acidosis: An Update
Background: The etiology of acute metabolic acidosis (aMA) is heterogeneous, and the consequences are potentially life-threatening. The aim of this article was to summarize the causes and management of aMA from a clinician ’s perspective.Summary: We performed a systematic search on PubMed, applying the following search terms: “acute metabolic acidosis,” “lactic acidosis,” “metformin” AND “acidosis,” “unbalanced solutions” AND “acidosis,” “bicarbonate” AND “acidosis” AND “outcome,” “acute metabolic acidosis” AND “management,” and “acute metabolic acidosis” AND “renal repla...
Source: Kidney and Blood Pressure Research - July 14, 2020 Category: Urology & Nephrology Source Type: research
Calcium channel blockers for people with chronic kidney disease requiring dialysis.
CONCLUSIONS: The benefits of CCBs over other antihypertensives on predialysis blood pressure levels and intradialytic hypotension among people with CKD who required haemodialysis were uncertain. Effects of CCBs on other side effects and cardiovascular death also remain uncertain. Dihydropyridine CCBs may decrease predialysis systolic and diastolic blood pressure level compared to placebo or no treatment. No studies were identified in children or peritoneal dialysis. Available studies have not been designed to measure the effects on costs. The shortcomings of the studies were that they recruited very few participants, had f...
Source: Cochrane Database of Systematic Reviews - September 30, 2020 Category: General Medicine Authors: Mugendi GA, Mutua FM, Natale P, Esterhuizen TM, Strippoli GF Tags: Cochrane Database Syst Rev Source Type: research
Low protein diets for non-diabetic adults with chronic kidney disease.
CONCLUSIONS: This review found that very low protein diets probably reduce the number of people with CKD 4 or 5, who progress to ESKD. In contrast low protein diets may make little difference to the number of people who progress to ESKD. Low or very low protein diets probably do not influence death. However there are limited data on adverse effects such as weight differences and protein energy wasting. There are no data on whether quality of life is impacted by difficulties in adhering to protein restriction. Studies evaluating the adverse effects and the impact on quality of life of dietary protein restriction are require...
Source: Cochrane Database of Systematic Reviews - October 29, 2020 Category: General Medicine Authors: Hahn D, Hodson EM, Fouque D Tags: Cochrane Database Syst Rev Source Type: research
Interventions for itch in people with advanced chronic kidney disease.
CONCLUSIONS: The RCTs of this meta-analysis contain a large array of interventions with a diverse set of comparators. For many interventions, trials are sparse. This served to make informative meta-analysis challenging. Of all treatments for uraemic pruritus, gabapentinoids (gabapentin and pregabalin) were the most studied and show the greatest reduction in itch scores. Further RCTs, even of the scale of the largest trials included in this review, are unlikely to significantly change this finding. Kappa-opioid agonists (mainly nalfurafine) also may reduce itch, but indirect comparison suggests a much more modest effect in ...
Source: Cochrane Database of Systematic Reviews - December 7, 2020 Category: General Medicine Authors: Hercz D, Jiang SH, Webster AC Tags: Cochrane Database Syst Rev Source Type: research
Urgent-start peritoneal dialysis versus haemodialysis for people with chronic kidney disease.
CONCLUSIONS: Compared with HD initiated using a CVC, urgent-start PD may reduce the risk of bacteraemia and had uncertain effects on other complications of dialysis and technique and patient survival. In summary, there are very few studies directly comparing the outcomes of urgent-start PD and HD initiated using a CVC for patients with CKD who need to commence dialysis urgently. This evidence gap needs to be addressed in future studies.
PMID: 33501650 [PubMed - in process]
Source: Cochrane Database of Systematic Reviews - January 27, 2021 Category: General Medicine Authors: Htay H, Johnson DW, Craig JC, Teixeira-Pinto A, Hawley CM, Cho Y Tags: Cochrane Database Syst Rev Source Type: research
Aldosterone antagonists for people with chronic kidney disease requiring dialysis.
CONCLUSIONS: Based on moderate certainty of the evidence, aldosterone antagonists probably reduces the risk of all-cause and cardiovascular death and probably reduces morbidity due to cardiovascular and cerebrovascular disease in people with CKD requiring dialysis. For the adverse effect of gynaecomastia, the risk was increased compared to control. For this outcome, the absolute risk was lower than the absolute risk of death. It is hoped the three large ongoing studies will provide better certainty of evidence.
PMID: 33586138 [PubMed - in process]
Source: Cochrane Database of Systematic Reviews - February 15, 2021 Category: General Medicine Authors: Hasegawa T, Nishiwaki H, Ota E, Levack WM, Noma H Tags: Cochrane Database Syst Rev Source Type: research
Tenapanor: A new treatment option for hyperphosphatemia in end stage kidney disease
CONCLUSIONS: Tenapanor is the first drug in its class that lowers hyperphosphatemia in ESKD patients through a novel mechanism of action involving paracellular inactive transport. Although more studies are needed, early results indicate that tenapanor may have a place in managing hyperphosphatemia in ESKD patients both as monotherapy and as an adjunct to existing phosphate binder therapy.PMID:35041802 | DOI:10.18433/jpps32284
Source: Journal of Pharmacy and Pharmaceutical Sciences - January 18, 2022 Category: Drugs & Pharmacology Authors: Tiffany Lin Akram Al-Makki Brian Shepler Source Type: research
